|
Market Closed -
Nasdaq
20:19:41 10/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.1400 USD | +8.69% |
|
-8.50% | -83.53% |
| 08-14 | CASI Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 08-14 | Casi Pharmaceuticals, Inc. Announces Management Changes | CI |
| Market Cap | 2.88M 2.48M 2.35M 2.13M 3.99M 275M 4.01M 27.88M 10.72M 140M 10.81M 10.57M 442M | P/E 2024 |
-1.11x | P/E 2025 | -0.33x |
|---|---|---|---|---|---|
| Enterprise Value | 24.73M 21.31M 20.18M 18.29M 34.31M 2.36B 34.48M 240M 92.15M 1.2B 92.88M 90.84M 3.8B | EV / Sales 2024 |
1.75x | EV / Sales 2025 | 1.9x |
| Free-Float |
53.62% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 week | 0.13 |  | 0.14 |
| 1 month | 0.13 | | 0.16 |
| 3 years | 0.05 | | 8.48 |
| 5 years | 0.05 | | 15.7 |
| 10 years | 0.05 | | 88.92 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Cory
CEO | Chief Executive Officer | 62 | 21/07/2025 |
Kun Qian
DFI | Director of Finance/CFO | 44 | 16/05/2025 |
Chun Hua Wang
COO | Chief Operating Officer | 54 | 01/01/2017 |
| Director | Title | Age | Since |
|---|---|---|---|
Yue Wu
BRD | Director/Board Member | 62 | 01/04/2013 |
Zhen Bo Su
BRD | Director/Board Member | 50 | 21/03/2023 |
Thomas Folinsbee
BRD | Director/Board Member | 59 | 21/03/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +8.69% | -8.50% | - | - | 2.88M | |
| -0.65% | -2.93% | +47.70% | +86.17% | 994B | |
| -0.29% | -3.51% | +49.15% | +62.35% | 640B | |
| +0.83% | +0.26% | +17.76% | +72.25% | 454B | |
| -0.38% | -3.59% | +30.13% | +35.17% | 337B | |
| -0.09% | -13.54% | +13.34% | +24.95% | 261B | |
| -0.43% | -2.48% | -0.73% | +9.58% | 246B | |
| -1.34% | -13.70% | +36.53% | +44.96% | 204B | |
| -3.44% | -7.51% | -20.63% | -59.44% | 190B | |
| -0.75% | -4.82% | +25.46% | +87.14% | 178B | |
| Average | -0.73% | -5.76% | +22.08% | +40.35% | 389.42B | |
| Weighted average by Cap. | -0.51% | -4.42% | +30.96% | +54.95% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 28.54M 24.59M 23.28M 21.1M 39.59M 2.73B 39.79M 277M 106M 1.39B 107M 105M 4.38B | 20.71M 17.85M 16.9M 15.32M 28.73M 1.98B 28.88M 201M 77.17M 1.01B 77.79M 76.08M 3.18B |
| Net income | -39.26M -33.82M -32.03M -29.03M -54.46M -3.75B -54.74M -380M -146M -1.91B -147M -144M -6.03B | -48.06M -41.41M -39.21M -35.54M -66.67M -4.59B -67.01M -466M -179M -2.34B -180M -177M -7.38B |
| Net Debt | 6.05M 5.21M 4.94M 4.47M 8.39M 578M 8.44M 58.62M 22.54M 294M 22.72M 22.22M 929M | 21.85M 18.83M 17.83M 16.16M 30.32M 2.09B 30.47M 212M 81.43M 1.06B 82.07M 80.27M 3.36B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/09/26 | $0.000000 | -100.00% | 146 |
| 10/09/26 | $0.1400 | +8.69% | 3,015 |
| 09/09/26 | $0.1288 | -4.59% | 6,342 |
| 08/09/26 | $0.1350 | -11.76% | 12,155 |
| 04/09/26 | $0.1530 | 0.00% | 682 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CASIF Stock
- CASI Stock
Select your edition
All financial news and data tailored to specific country editions
